The post challenges the notion that effect sizes below 0.50 for medications are clinically insignificant, using antidepressants as a case study and comparing them to other common drugs.

Scott Alexander argues that despite some replication failures, the core of behavioral economics remains valid and valuable, with the field continuing to evolve and refine its understanding of human decision-making.

Scott Alexander warns about the potential misinterpretation of odds ratios in studies, explaining how to convert them to effect sizes for more accurate understanding.

Scott Alexander revisits his stance on SSRIs, discussing new meta-analyses, broader trends in psychiatric medication efficacy, and potential explanations for the discrepancy between statistical and clinical observations.

Scott reviews evidence on whether college improves critical thinking, finding modest short-term gains but questioning their long-term persistence.

Scott Alexander examines a study comparing the effectiveness of drugs and therapy for psychiatric disorders, discussing the results and methodological limitations of the research.

Scott analyzes various criticisms of antidepressants, concluding they have modest but real benefits over placebo, with important considerations about side effects and efficacy.